MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

High dose of levodopa and Segawa disease

M. Taghiyeva (Baku, Azerbaijan)

Meeting: 2018 International Congress

Abstract Number: 473

Keywords: Dopa-responsive dystonia(DRD), Levodopa(L-dopa)

Session Information

Date: Saturday, October 6, 2018

Session Title: Rare Genetic and Metabolic Diseases

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To analyze the dose-dependent effects of levodopa on the symptoms of the disease in our case.

Background: In 1976, Segawa et al. reported dopa-responsive dystonia (DRD) or Segawa disease that is an inherited dystonia which shows symptoms of dopamine decrement due to the deficiency of tyrosine hydroxylase in the terminal of the nigrostriatal dopamine neuron, which is caused by GCH-1 deficiency. DRD manifests itself during early childhood at around ages 5–8 years but also can have a late-onset(variable start age).

Methods: Here we describe a case of SD in a 33 year old man whose disease begun at the age of 15 with gait disturbance and Pes cavus of a right limb .There was no other apparent case of any hereditary disorder in the family . After laboratory investigations, imaging studies and the exclusion of other causes of childhood dystonia, the patient were diagnosed with Segawa syndrome.

Results: Treatment with low dose L-Dopa showed marked improvement. But patient began to increase L-dopa dose by itself till 2000 mg/day. Soon patient had a worsening of the disease and developed new miopathy symptoms. L-dopa dose was reduced and patient had improvement of symptoms.

Conclusions: So we suggest that L-dopa in hight doses can have negative effects on Segawa disease and requires strict control over its dose.

To cite this abstract in AMA style:

M. Taghiyeva. High dose of levodopa and Segawa disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/high-dose-of-levodopa-and-segawa-disease/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/high-dose-of-levodopa-and-segawa-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley